OVID on Nasdaq

Ovid Therapeutics Inc.

American pharmaceutical preparations company based in New York.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Whitehawk Therapeutics, Inc., Tvardi Therapeutics, Inc. or Xenon Pharmaceuticals, or pick any stock.

TickerOVID on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersNew York, United States
Incorporated inDE²
Business address441 Ninth Avenue, 14Th Floor, New York, Ny 10001²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-585.2%Operating margin³

-240.1%Net margin³

1181.3%Revenue growth, 2025³

-13.3%Return on equity³

-$38.3MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and development

Research and development100¢$25.6M

Out of $7.3M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷³$7.3M in 2025−43% since 2020

Operating income⁸⁴⁵⁶⁷³-$42.4M in 2025−31% since 2019

Net income⁸⁴⁵⁶⁷³-$17.4M in 2025−71% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Revenue	$7.3M	$566.0K
Research and development	$25.6M	$36.8M
General and administrative	$24.1M	$25.7M
Total operating expenses	$49.7M	$62.5M
Loss from operations	-$42.4M	-$61.9M
Other income (expense), net	$25.0M	$35.5M
Loss before provision for income taxes	-$17.4M	-$26.4M
Provision for income taxes	$0	$0
Net loss	-$17.4M	-$26.4M

Total assets⁸⁴⁵⁶⁷³$150.9M in 2025+87% since 2019

Total liabilities⁸⁴⁵⁶⁷³$20.3M in 2025+87% since 2019

Shareholders’ equity⁴⁵⁶⁷³$130.7M in 2025+87% since 2019

Cash⁸⁴⁵⁶⁷³$13.2M in 2025−69% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.³

Period ending	2025-12-31	2025-11-30	2024-12-31	2023-12-31
Cash and cash equivalents	$13.2M		$26.3M
Marketable securities	$56.5M		$26.8M
Prepaid expenses and other current assets	$4.7M		$2.9M
Total current assets	$74.4M		$55.9M
Marketable securities - noncurrent	$20.8M		$0
Long-term equity investments	$42.0M		$21.0M
Restricted cash	$1.9M		$1.9M
Right-of-use asset, net	$11.6M		$12.8M
Property and equipment, net	$252.0K		$433.0K
Other assets	$0		$92.0K
Total assets	$150.9M		$92.2M
Accounts payable	$2.0M		$3.2M
Accrued expenses	$4.9M		$6.0M
Current portion, lease liability	$1.4M		$1.3M
Total current liabilities	$8.3M		$10.5M
Lease liability	$12.0M		$13.4M
Total liabilities	$20.3M		$23.9M
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 0 and 1,250 shares issued and outstanding at December 31, 2025 and 2024, respectively	$0		$0
Common stock, $0.001 par value; 315,000,000 and 125,000,000 shares authorized; 130,184,353 and 71,009,866 shares issued and outstanding at December 31, 2025 and 2024, respectively	$130.0K		$71.0K
Additional paid-in-capital	$452.4M		$372.5M
Accumulated other comprehensive loss	-$202.0K		-$35.0K
Accumulated deficit	-$321.7M		-$304.3M
Total stockholders equity	$130.7M		$68.2M	$87.8M
Total liabilities and stockholders equity	$150.9M		$92.2M
Preferred stock, par value (in USD per share)	$0.00		$0.00
Preferred stock, shares authorized (in shares)	10.0M shares		10.0M shares
Preferred stock, share designated (in shares)	10.0K shares		10.0K shares
Preferred stock, shares issued (in shares)	0 shares		1.2K shares
Preferred stock, shares outstanding (in shares)	0 shares		1.2K shares
Common stock, par value (in dollars per share)	$0.00		$0.00
Common stock, shares authorized (in shares)	315.0M shares	125.0M shares	125.0M shares
Common stock, shares issued (in shares)	130.2M shares		71.0M shares
Common stock, shares outstanding (in shares)	130.2M shares		71.0M shares

Period ending	2025-12-31	2025-11-30	2024-12-31	2023-12-31
Cash and cash equivalents	$13.2M		$26.3M
Marketable securities	$56.5M		$26.8M
Prepaid expenses and other current assets	$4.7M		$2.9M
Total current assets	$74.4M		$55.9M
Marketable securities - noncurrent	$20.8M		$0
Long-term equity investments	$42.0M		$21.0M
Restricted cash	$1.9M		$1.9M
Right-of-use asset, net	$11.6M		$12.8M
Property and equipment, net	$252.0K		$433.0K
Other assets	$0		$92.0K
Total assets	$150.9M		$92.2M
Accounts payable	$2.0M		$3.2M
Accrued expenses	$4.9M		$6.0M
Current portion, lease liability	$1.4M		$1.3M
Total current liabilities	$8.3M		$10.5M
Lease liability	$12.0M		$13.4M
Total liabilities	$20.3M		$23.9M
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 0 and 1,250 shares issued and outstanding at December 31, 2025 and 2024, respectively	$0		$0
Common stock, $0.001 par value; 315,000,000 and 125,000,000 shares authorized; 130,184,353 and 71,009,866 shares issued and outstanding at December 31, 2025 and 2024, respectively	$130.0K		$71.0K
Additional paid-in-capital	$452.4M		$372.5M
Accumulated other comprehensive loss	-$202.0K		-$35.0K
Accumulated deficit	-$321.7M		-$304.3M
Total stockholders equity	$130.7M		$68.2M	$87.8M
Total liabilities and stockholders equity	$150.9M		$92.2M
Preferred stock, par value (in USD per share)	$0.00		$0.00
Preferred stock, shares authorized (in shares)	10.0M shares		10.0M shares
Preferred stock, share designated (in shares)	10.0K shares		10.0K shares
Preferred stock, shares issued (in shares)	0 shares		1.2K shares
Preferred stock, shares outstanding (in shares)	0 shares		1.2K shares
Common stock, par value (in dollars per share)	$0.00		$0.00
Common stock, shares authorized (in shares)	315.0M shares	125.0M shares	125.0M shares
Common stock, shares issued (in shares)	130.2M shares		71.0M shares
Common stock, shares outstanding (in shares)	130.2M shares		71.0M shares

Cash from operations⁸⁴⁵⁶⁷³-$38.3M in 2025−25% since 2019

Capital spending⁸⁴⁵⁶⁷³$0 in 2025

Free cash flow⁸⁴⁵⁶⁷³-$38.3M in 2025−25% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Net loss	-$17.4M	-$26.4M
Change in fair value of royalty monetization liability	$0	-$30.0M
Unrealized gain on equity investments	-$21.1M	-$3.3M
Change in accrued interest and accretion of discount on marketable securities	-$695.0K	-$2.8M
Stock-based compensation expense	$4.8M	$6.3M
Depreciation and amortization expense	$273.0K	$613.0K
Noncash operating lease expense	$1.2M	$1.1M
Change in lease liability	-$1.3M	-$1.2M
Prepaid expenses and other current assets	-$1.8M	$899.0K
Accounts payable	-$1.2M	-$512.0K
Accrued expenses	-$1.1M	-$537.0K
Net cash used in operating activities	-$38.3M	-$56.0M
Purchase of marketable securities	-$91.9M	-$73.2M
Sales/maturities of marketable securities	$42.0M	$128.0M
Purchases of property and equipment	$0	-$71.0K
Software development and other costs	$0	-$90.0K
Net cash (used in) provided by investing activities	-$49.9M	$54.6M
Proceeds from private placement financing, net of transaction costs	$75.1M	$0
Proceeds from exercise of options and employee stock purchase plan	$91.0K	$622.0K
Net cash provided by financing activities	$75.2M	$622.0K
Effect of exchange rates on cash, cash equivalents and restricted cash	-$167.0K	$0
Net decrease in cash, cash equivalents and restricted cash	-$13.1M	-$740.0K

Compare Ovid Therapeutics Inc. with another company

Leadership

Who has led Ovid Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Jeremy M. Levin2026–now

President

Chief financial officer

Chief operating officer

20202025

Chief executive officerMargaret A. Alexander Jan 5, 2026 to now¹¹
Chief executive officerJeremy M. Levin May 4, 2017 to Jan 5, 2026¹²
ChairJeremy M. Levin Mar 25, 2026 to now¹³
PresidentMargaret A. Alexander Sep 11, 2024 to now¹⁴
PresidentAmit Rakhit Nov 4, 2019 to Jul 16, 2021¹⁵
PresidentMatthew During May 4, 2017 to Feb 26, 2019¹⁶
Chief financial officerCharles Ross Carter Jul 8, 2026 to now¹⁷
Chief financial officerYaron Werber May 4, 2017 to Jan 23, 2018¹⁸
Chief operating officerMargaret A. Alexander Sep 11, 2024 to now¹⁴
Chief operating officerJason Tardio Feb 4, 2022 to Feb 26, 2024¹⁹

Board members and other officers (16)

Chief Business OfficerJeffrey A. Rona Oct 2, 2020 to now²⁰
Chief Commercial OfficerJason Tardio Nov 21, 2019 to Jul 1, 2021²¹
CMO and PMOAmit Rakhit May 4, 2017 to Apr 3, 2019²²
SVP, Global Regulatory AffairsDirk Haasner May 4, 2017 to Dec 21, 2020²³
VP, Finance & Corp. ControllerTimothy Daly May 4, 2017 to Dec 21, 2020²⁴
Board memberMargaret A. Alexander Jan 5, 2026 to now¹¹
Board memberAnna Greka Jun 17, 2026 to now²⁵
Board memberStelios Papadopoulos Mar 4, 2025 to now²⁶
Board memberBart Friedman May 4, 2017 to now²⁷
Board memberDouglas E. Williams May 4, 2017 to May 18, 2021²⁸
Board memberJeremy M. Levin May 4, 2017 to now¹²
Board memberKaren Bernstein May 4, 2017 to now²⁹
Board memberMatthew During May 4, 2017 to Apr 3, 2019¹⁶
Board memberBarbara Gayle Duncan Jun 15, 2017 to now³⁰
General counselThomas Michael Perone Mar 26, 2019 to Feb 26, 2024³¹
General counselAna Ward Sep 6, 2017 to Feb 26, 2019³²

Timeline

Jan 5, 2026New chief executive Margaret A. Alexander becomes CEO¹¹
May 4, 2017New chief executive Jeremy M. Levin becomes CEO¹²
Apr 1, 2014Founded Ovid Therapeutics Inc. is founded³³

Filings

232 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 50 major events, 79 insider forms, 43 large holders, 39 other. The latest 20:

Aug 24, 2026144 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026144 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Aug 13, 2026SCHEDULE 13G/A EDGAR
Jul 29, 2026SCHEDULE 13G EDGAR
Jul 8, 20264 EDGAR
Jul 8, 20263 EDGAR
Jul 8, 20268-K EDGAR
Jul 8, 2026SCHEDULE 13G/A EDGAR
Jun 17, 20264 EDGAR
Jun 17, 20263 EDGAR
Jun 11, 20268-K EDGAR
Jun 3, 20268-K EDGAR
May 15, 2026SCHEDULE 13G EDGAR
May 15, 2026SCHEDULE 13G EDGAR

The 232 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 43 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jupiter Topco LLC	20,741,234	$55.9M	0.0%	New
Eventide Asset Management, LLC	11,812,241	$31.8M	0.4%	+1,895,330
BlackRock, Inc.	10,823,480	$29.1M	0.0%	+9,290,197
Ra Capital Management, L.P.	10,500,968	$28.2M	0.2%	−213,032
Affinity Asset Advisors, LLC	10,144,562	$27.3M	1.4%	−491,756
State Street Corp	7,900,765	$21.3M	0.0%	+7,380,482
Vanguard Capital Management LLC	7,760,114	$20.9M	0.0%	+2,501,868
ADAR1 Capital Management, LLC	7,417,479	$20.0M	0.9%	+2,873,366
Balyasny Asset Management L.P.	6,719,076	$18.1M	0.0%	+1,186,003
Adage Capital Partners Gp, L.l.c.	6,163,781	$16.6M	0.0%	No change
Federated Hermes, Inc.	5,951,666	$16.0M	0.0%	+2,380,666
Braidwell LP	5,919,464	$15.9M	0.6%	New
Geode Capital Management, LLC	4,072,653	$11.0M	0.0%	+2,754,562
Silverarc Capital Management, LLC	3,101,129	$8.3M	0.9%	+2,101,129
Stempoint Capital LP	2,417,283	$6.5M	1.1%	New
Ikarian Capital, LLC	2,269,704	$6.1M	1.0%	−625,000
Point72 Asset Management, L.P.	1,945,727	$5.2M	0.0%	+625,117
Sphera Funds Management Ltd.	1,353,000	$3.6M	0.5%	−269,828
Northern Trust Corp	1,246,139	$3.4M	0.0%	+991,335
Vanguard Fiduciary Trust Co	1,140,753	$3.1M	0.0%	+447,497
Propel Bio Management, LLC	1,115,538	$3.0M	1.6%	+194,081
Rosalind Advisors, Inc.	1,107,994	$3.0M	1.1%	No change
Vanguard Portfolio Management LLC	1,030,943	$2.8M	0.0%	New
Sio Capital Management, LLC	1,005,334	$2.7M	0.5%	−247,047
Ensign Peak Advisors, Inc	988,084	$2.7M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAROvid Therapeutics Inc. filings on SEC EDGAR
2
SEC EDGAROvid Therapeutics Inc. filings on SEC EDGAR
3
SEC EDGAROvid Therapeutics Inc. 10-K for fiscal 2025
4
SEC EDGAROvid Therapeutics Inc. 10-K for fiscal 2020
5
SEC EDGAROvid Therapeutics Inc. 10-K for fiscal 2021
6
SEC EDGAROvid Therapeutics Inc. 10-K for fiscal 2022
7
SEC EDGAROvid Therapeutics Inc. 10-K for fiscal 2023
8
SEC EDGAROvid Therapeutics Inc. 10-K for fiscal 2019
9
SEC EDGAROvid Therapeutics Inc. 10-Q for fiscal 2026
10
SEC EDGAROvid Therapeutics Inc. 10-Q for fiscal 2026
11
SEC EDGARMargaret A. Alexander, Chief executive officer
12
SEC EDGARJeremy M. Levin, Chief executive officer
13
SEC EDGARJeremy M. Levin, Chair
14
SEC EDGARMargaret A. Alexander, President
15
SEC EDGARAmit Rakhit, President
16
SEC EDGARMatthew During, President
17
SEC EDGARCharles Ross Carter, Chief financial officer
18
SEC EDGARYaron Werber, Chief financial officer
19
SEC EDGARJason Tardio, Chief operating officer
20
SEC EDGARJeffrey A. Rona, Chief Business Officer
21
SEC EDGARJason Tardio, Chief Commercial Officer
22
SEC EDGARAmit Rakhit, CMO and PMO
23
SEC EDGARDirk Haasner, SVP, Global Regulatory Affairs
24
SEC EDGARTimothy Daly, VP, Finance & Corp. Controller
25
SEC EDGARAnna Greka, Board member
26
SEC EDGARStelios Papadopoulos, Board member
27
SEC EDGARBart Friedman, Board member
28
SEC EDGARDouglas E. Williams, Board member
29
SEC EDGARKaren Bernstein, Board member
30
SEC EDGARBarbara Gayle Duncan, Board member
31
SEC EDGARThomas Michael Perone, General counsel
32
SEC EDGARAna Ward, General counsel
33
gleifOvid Therapeutics Inc. is founded